Advanced Nanocarriers for Cancer Therapies: Recent Developments and Clinical Challenges
Abstract
Cancer remains a major global health challenge, accounting for substantial morbidity and mortality despite advances in surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapies. However, the clinical effectiveness of these treatments is frequently limited by poor drug specificity, systemic toxicity, multidrug resistance, rapid drug clearance, and inadequate accumulation within tumor tissues. Advanced nanocarrier systems have emerged as a promising strategy to overcome these limitations by improving drug solubility, pharmacokinetics, tumor-targeted delivery, and therapeutic efficacy. This review critically summarizes recent developments in advanced nanocarriers for cancer therapy, emphasizing their design principles, therapeutic applications, clinical translation, and the key challenges influencing their future clinical adoption. The selected studies were critically analyzed to compare different nanocarrier platforms, targeting strategies, therapeutic performance, clinical progress, biosafety, manufacturing considerations, and regulatory perspectives. Recent advances demonstrate that lipid-based, polymeric, inorganic, biomimetic, and hybrid nanocarriers significantly enhance targeted drug delivery, improve therapeutic efficacy, and reduce systemic toxicity. Multifunctional and stimuli-responsive nanoplatforms have further expanded opportunities for precision oncology, although challenges related to safety, scalability, and regulatory approval remain. Advanced nanocarriers represent a promising platform for next-generation cancer therapeutics. Continued optimization of nanocarrier design, comprehensive safety evaluation, standardized manufacturing, and well-designed clinical studies will be essential to facilitate their successful translation into routine oncology practice.
Keywords: Advanced Nanocarriers; Cancer Therapy; Targeted Drug Delivery Nanomedicine; Precision Oncology.
Keywords:
Advanced Nanocarriers, Cancer Therapy, Targeted Drug Delivery Nanomedicine, Precision OncologyDOI
https://doi.org/10.22270/jddt.v16i9.7989References
1. Fernandese Silva E, FdS F, Lettnin AP, et al. C-Phycocyanin: cellular targets, mechanisms of action and multi drug resistance in cancer. Pharmacol Rep. 2018;70:75–80. doi: 10.1016/j.pharep.2017.07.018 [DOI] [PubMed] [Google Scholar]
2. Henn JG, Aguirre TAS, Nugent M, Moura DJ. Cancer nanomedicine: recent developments in drug delivery systems and strategies to overcome eventual barriers to achieve a better outcome. J Drug Delivery Sci Technol. 2024;91:105254. doi: 10.1016/j.jddst.2023.105254 [DOI] [Google Scholar]
3. Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J hematol oncol. 2021;14:1–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
4. Rashidi N, Davidson M, Apostolopoulos V, Nurgali K. Nanoparticles in cancer diagnosis and treatment: progress, challenges, and opportunities. J Drug Delivery Sci Technol. 2024;95:105599. doi: 10.1016/j.jddst.2024.105599 [DOI] [Google Scholar]
5. Sell M, Lopes AR, Escudeiro M, et al. Application of nanoparticles in cancer treatment: a concise review. Nanomaterials. 2023;13(21):2887. doi: 10.3390/nano13212887 [DOI] [PMC free article] [PubMed] [Google Scholar]
6. Pandita D, Poonia N, Chaudhary G, Jain GK, Lather V, Khar RK. pH-sensitive polymeric nanocarriers for enhanced intracellular drug delivery. In: Smart Polymeric Nano-Constructs in Drug Delivery. Elsevier; 2023:65–107. [Google Scholar]
7. Ashique S, Faiyazuddin M, Afzal O, et al. Advanced nanoparticles, the hallmark of targeted drug delivery for osteosarcoma-an updated review. J Drug Delivery Sci Technol. 2023;87:104753. doi: 10.1016/j.jddst.2023.104753 [DOI] [Google Scholar]
8. Ai J, Biazar E, Jafarpour M, et al. Nanotoxicology and nanoparticle safety in biomedical designs. Int J Nanomed;2011. 1117–1127. doi: 10.2147/IJN.S16603 [DOI] [PMC free article] [PubMed] [Google Scholar]
9. Elumalai K, Srinivasan S, Shanmugam A. Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomed Technol. 2024;5:109–122. doi: 10.1016/j.bmt.2023.09.001 [DOI] [Google Scholar]
10. Haider M, Elsherbeny A, Pittalà V, et al. Nanomedicine strategies for management of drug resistance in lung cancer. Int J Mol Sci. 2022;23(3):1853. doi: 10.3390/ijms23031853 [DOI] [PMC free article] [PubMed] [Google Scholar]
11. Qu H, Chen H, Cheng W, et al. A supramolecular assembly strategy for hydrophilic drug delivery towards synergistic cancer treatment. Acta Biomater. 2023;164:407–421. doi: 10.1016/j.actbio.2023.04.026 [DOI] [PubMed] [Google Scholar]
12. Ahmad W, Khan T, Basit I, Imran J. A comprehensive review on targeted drug delivery system. Asian J Pharmaceutical Res. 2022;12(4):335–340. doi: 10.52711/2231-5691.2022.00053 [DOI] [Google Scholar]
13. Song Y, Zou J, Castellanos EA, et al. Theranostics-a sure cure for cancer after 100 years? Theranostics. 2024;14(6):2464. doi: 10.7150/thno.96675 [DOI] [PMC free article] [PubMed] [Google Scholar]
14. Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. Nanoparticles in cancer theragnostic and drug delivery: a comprehensive review. Life Sci. 2024;352:122899. doi: 10.1016/j.lfs.2024.122899 [DOI] [PubMed] [Google Scholar]
15. Davodabadi F, Sajjadi SF, Sarhadi M, et al. Cancer chemotherapy resistance: mechanisms and recent breakthrough in targeted drug delivery. Eur J Pharmacol. 2023;958:176013. doi: 10.1016/j.ejphar.2023.176013 [DOI] [PubMed] [Google Scholar]
16. Duan C, Yu M, Xu J, Li B-Y, Zhao Y, Kankala RK. Overcoming Cancer Multi-drug Resistance (MDR): reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomed. Pharmacother. 2023;162:114643. doi: 10.1016/j.biopha.2023.114643 [DOI] [PubMed] [Google Scholar]
17. Pote MS, Gacche RN. ATP-binding cassette efflux transporters and MDR in cancer. Drug Discovery Today. 2023;28(5):103537. doi: 10.1016/j.drudis.2023.103537 [DOI] [PubMed] [Google Scholar]
18. Wang C, Li F, Zhang T, Yu M, Sun Y. Recent advances in anti-multidrug resistance for nano-drug delivery system. Drug Delivery. 2022;29(1):1684–1697. doi: 10.1080/10717544.2022.2079771 [DOI] [PMC free article] [PubMed] [Google Scholar]
19. Kurmi BD, Patel P, Paliwal R, Paliwal SR. Molecular approaches for targeted drug delivery towards cancer: a concise review with respect to nanotechnology. J Drug Delivery Sci Technol. 2020;57:101682. [Google Scholar]
20. Shaik R, Malik MS, Basavaraju S, et al. Cellular and molecular aspects of drug resistance in cancers. DARU J Pharma Sci. 2025;33(1):1–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
21. Bharathiraja P, Yadav P, Sajid A, Ambudkar SV, Prasad NR. Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer. Drug Resist Updates. 2023;71:101004. doi: 10.1016/j.drup.2023.101004 [DOI] [PMC free article] [PubMed] [Google Scholar]
22. Liu J, Cabral H, Mi P. Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release. Adv Drug Delivery Rev. 2024;115239. doi: 10.1016/j.addr.2024.115239 [DOI] [PubMed] [Google Scholar]
23. Wang M, Chen W, Chen J, et al. Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies. Eur J Med Chem. 2021;220:113487. doi: 10.1016/j.ejmech.2021.113487 [DOI] [PubMed] [Google Scholar]
24. Mir SA, Hamid L, Bader GN, et al. Role of nanotechnology in overcoming the multidrug resistance in cancer therapy: a review. Molecules. 2022;27(19):6608. doi: 10.3390/molecules27196608 [DOI] [PMC free article] [PubMed] [Google Scholar]
25. Puris E, Fricker G, Gynther M. The role of solute carrier transporters in efficient anticancer drug delivery and therapy. Pharmaceutics. 2023;15(2):364. doi: 10.3390/pharmaceutics15020364 [DOI] [PMC free article] [PubMed] [Google Scholar]
26. Mynott RL, Wallington-Beddoe CT. Drug and solute transporters in mediating resistance to novel therapeutics in multiple myeloma. ACS Pharmacol Transl Sci. 2021;4(3):1050–1065. doi: 10.1021/acsptsci.1c00074 [DOI] [PMC free article] [PubMed] [Google Scholar]
27. Pachani S, Shah TM. Formulation of paclitaxel-encapsulated polymeric micelles for targeted breast cancer therapy. J Popul Ther Clin Pharmacol. 2021;28(2):936–951. doi:10.53555/m318xt37. Journal of Population Therapeutics
28. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7(3):339. doi: 10.15171/apb.2017.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
29. Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72(5):1125–1151. doi: 10.1007/s43440-020-00138-7 [DOI] [PubMed] [Google Scholar]
30. Kadhum WR, Majeed AA, Saleh RO, et al. Overcoming drug resistance with specific nano scales to targeted therapy: focused on metastatic cancers. Pathol Res Pract. 2024;255:155137. doi: 10.1016/j.prp.2024.155137 [DOI] [PubMed] [Google Scholar]
31. Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers. 2014;6(3):1769–1792. doi: 10.3390/cancers6031769 [DOI] [PMC free article] [PubMed] [Google Scholar]
32. Ortíz R, Quiñonero F, García-Pinel B, et al. Nanomedicine to overcome multidrug resistance mechanisms in colon and pancreatic cancer: recent progress. Cancers. 2021;13(9):2058. doi: 10.3390/cancers13092058 [DOI] [PMC free article] [PubMed] [Google Scholar]
33. Mowla M, Hashemi A. Functional roles of exosomal miRNAs in multi-drug resistance in cancer chemotherapeutics. Exp Mol Pathol. 2021;118:104592. doi: 10.1016/j.yexmp.2020.104592 [DOI] [PubMed] [Google Scholar]
34. Ying Z, Wenjing S, Jing B, Songbin F, Kexian D. Advances in long non-coding RNA regulating drug resistance of cancer. Gene. 2023;887:147726. doi: 10.1016/j.gene.2023.147726 [DOI] [PubMed] [Google Scholar]
35. Shi Y, Adu-Amankwaah J, Zhao Q, et al. Long non-coding RNAs in drug resistance across the top five cancers: update on their roles and mechanisms. Heliyon. 2024;2024:1. [DOI] [PMC free article] [PubMed] [Google Scholar]
36. Zhou X, Ao X, Jia Z, et al. Non-coding RNA in cancer drug resistance: underlying mechanisms and clinical applications. Front Oncol. 2022;12:951864. doi: 10.3389/fonc.2022.951864 [DOI] [PMC free article] [PubMed] [Google Scholar]
37. Yan T, Tian X, Liu F, et al. The emerging role of circular RNAs in drug resistance of non-small cell lung cancer. Front Oncol. 2022;12:1003230. doi: 10.3389/fonc.2022.1003230 [DOI] [PMC free article] [PubMed] [Google Scholar]
38. Misir S, Yaman SO, Petrović N, Sumer C, Hepokur C, Aliyazicioglu Y. circRNAs in drug resistance of breast cancer. Oncol Res. 2022;30(4):157. doi: 10.32604/or.2022.027547 [DOI] [PMC free article] [PubMed] [Google Scholar]
39. Emran TB, Shahriar A, Mahmud AR, et al. Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol. 2022;12:891652. [DOI] [PMC free article] [PubMed] [Google Scholar]
40. Gong S, Shang M, Li D, Cai Y, Jin J, Yang Z. Functionalized ZIF‐90 for gene‐mediated chemotherapy to ameliorate multidrug resistance in breast cancer therapy. ChemNanoMat. 2022;8(2):e202100389. doi: 10.1002/cnma.202100389 [DOI] [Google Scholar]
41. Deng F, Sistonen J, Neuvonen M, Niemi M. Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors. Basic Clin Physiol Pharmacol. 2023;133(4):428–436. doi: 10.1111/bcpt.13928 [DOI] [PubMed] [Google Scholar]
42. Zhang H, You J, Liu W, Chen D, Zhang S, Wang X. The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: a systematic review and meta-analysis. Medicine. 2021;100(30):e26714. doi: 10.1097/MD.0000000000026714 [DOI] [PMC free article] [PubMed] [Google Scholar]
43. Ashique S, Garg A, Farid A, Hussain A, Kumar P, Taghizadeh‐Hesary F. Nanodelivery systems: an efficient and target‐specific approach for drug‐resistant cancers. Cancer Med. 2023;12(18):18797–18825. doi: 10.1002/cam4.6502 [DOI] [PMC free article] [PubMed] [Google Scholar]
44. Dunuweera SP, Rajapakse RMSI, Rajapakshe RBSD, et al. Review on targeted drug delivery carriers used in nanobiomedical applications. Curr Nanosci. 2019;15(4):382–397. doi: 10.2174/1573413714666181106114247 [DOI] [Google Scholar]
45. Dave P, Raval B, Mori D, Dudhat K. Targeted nanotechnology in bone cancer: integrating stimuli responsive drug delivery and artificial intelligence for personalized therapy. Nano Trends. 2026 Jan 10:100182.
46. Navya P, Kaphle A, Srinivas S, Bhargava SK, Rotello VM, Daima HK. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Convergence. 2019;6(1):23. doi: 10.1186/s40580-019-0193-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
47. Yan S, Na J, Liu X, Wu P. Different targeting ligands-mediated drug delivery systems for tumor therapy. Pharmaceutics. 2024;16(2):248. doi: 10.3390/pharmaceutics16020248 [DOI] [PMC free article] [PubMed] [Google Scholar]
48. Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov. 2023;22(3):213–234. doi: 10.1038/s41573-022-00615-z [DOI] [PubMed] [Google Scholar]
49. Ejigah V, Owoseni O, Bataille-Backer P, Ogundipe OD, Fisusi FA, Adesina SK. Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect. Polymers. 2022;14(13):2601. doi: 10.3390/polym14132601 [DOI] [PMC free article] [PubMed] [Google Scholar]
50. Chen H-A, Lu Y-J, Dash BS, Chao Y-K, Chen J-P. Hyaluronic acid-modified cisplatin-encapsulated poly (lactic-co-glycolic acid) magnetic nanoparticles for dual-targeted NIR-responsive chemo-photothermal combination cancer therapy. Pharmaceutics. 2023;15(1):290. doi: 10.3390/pharmaceutics15010290 [DOI] [PMC free article] [PubMed] [Google Scholar]
51. Chouhan RS, Horvat M, Ahmed J, Alhokbany N, Alshehri SM, Gandhi S. Magnetic nanoparticles—A multifunctional potential agent for diagnosis and therapy. Cancers. 2021;13(9):2213. doi: 10.3390/cancers13092213 [DOI] [PMC free article] [PubMed] [Google Scholar]
52. Huber CM, Pavan TZ, Ullmann I, et al. A review on ultrasound-based methods to image the distribution of magnetic nanoparticles in biomedical applications. Ultrasound Med Biol. 2024;2024:1. [DOI] [PubMed] [Google Scholar]
53. Yagublu V, Karimova A, Hajibabazadeh J, et al. Overview of physicochemical properties of nanoparticles as drug carriers for targeted cancer therapy. J Funct Biomat. 2022;13(4):196. doi: 10.3390/jfb13040196 [DOI] [PMC free article] [PubMed] [Google Scholar]
54. Zhao Z, Ukidve A, Krishnan V, Mitragotri S. Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers. Adv Drug Delivery Rev. 2019;143:3–21. doi: 10.1016/j.addr.2019.01.002 [DOI] [PubMed] [Google Scholar]
55. Yue J, Feliciano TJ, Li W, Lee A, Odom TW. Gold nanoparticle size and shape effects on cellular uptake and intracellular distribution of siRNA nanoconstructs. Bioconjugate Chem. 2017;28(6):1791–1800. doi: 10.1021/acs.bioconjchem.7b00252 [DOI] [PMC free article] [PubMed] [Google Scholar]
56. Lagarrigue P, Moncalvo F, Cellesi F. Non-spherical polymeric nanocarriers for therapeutics: the effect of shape on biological systems and drug delivery properties. Pharmaceutics. 2022;15(1):32. doi: 10.3390/pharmaceutics15010032 [DOI] [PMC free article] [PubMed] [Google Scholar]
57. Soltani M, Souri M, Moradi Kashkooli F. Effects of hypoxia and nanocarrier size on pH-responsive nano-delivery system to solid tumors. Sci Rep. 2021;11(1):19350. doi: 10.1038/s41598-021-98638-w [DOI] [PMC free article] [PubMed] [Google Scholar]
58. Zaky MF, Youssef YL, Megahed MA. Impact of surface design and coating on the efficacy of nano-carriers as drug delivery systems: a review. ERU Res J. 2023;2(3):415–446. doi: 10.21608/erurj.2023.219322.1045 [DOI] [Google Scholar]
59. Zhang P, Chen D, Li L, Sun K. Charge reversal nano-systems for tumor therapy. J Nanobiotechnol. 2022;20:1–27. doi: 10.1186/s12951-021-01184-w [DOI] [PMC free article] [PubMed] [Google Scholar]
60. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nano-Enabled Med Appl. 2020;2020:61–91. [DOI] [PubMed] [Google Scholar]
61. Liu J, Sun B, Li W, et al. Wireless sequential dual light delivery for programmed PDT in vivo. Light Sci Appl. 2024;13(1):113. doi: 10.1038/s41377-024-01437-x [DOI] [PMC free article] [PubMed] [Google Scholar]
62. Liu ZS, Wen J, Huang CY, et al. Nanomedicines based on responsive nanocarriers for cancer therapy. Adv Ther. 2024;7(2):2300223. doi: 10.1002/adtp.202300223 [DOI] [Google Scholar]
63. Wang Y, Yu W, Niu C, et al. A NIR light-activated PLGA microsphere for controlled release of mono-or dual-drug. Polym Test. 2022;116:107762. doi: 10.1016/j.polymertesting.2022.107762 [DOI] [Google Scholar]
64. Waheed I, Ali A, Tabassum H, Khatoon N, Lai W-F, Zhou X. Lipid-based nanoparticles as drug delivery carriers for cancer therapy. Front Oncol. 2024;14:1. [DOI] [PMC free article] [PubMed] [Google Scholar]
65. Zhao Y-Q, Li L-J, Zhou E-F, et al. Lipid-based nanocarrier systems for drug delivery: advances and applications. Pharmaceutical Fronts. 2022;4(02):e43–e60. doi: 10.1055/s-0042-1751036 [DOI] [Google Scholar]
66. Priya S, Desai VM, Singhvi G. Surface modification of lipid-based nanocarriers: a potential approach to enhance targeted drug delivery. ACS omega. 2022;8(1):74–86. doi: 10.1021/acsomega.2c05976 [DOI] [PMC free article] [PubMed] [Google Scholar]
67. Ramadan E, Ahmed A, Naguib YW. Advances in mRNA LNP-based cancer vaccines: mechanisms, formulation aspects, challenges, and future directions. J Personalized Med. 2024;14(11):1092. doi: 10.3390/jpm14111092 [DOI] [PMC free article] [PubMed] [Google Scholar]
68. Hamad I, Harb AA, Bustanji Y. Liposome-based drug delivery systems in cancer research: an analysis of global landscape efforts and achievements. Pharmaceutics. 2024;16(3):400. doi: 10.3390/pharmaceutics16030400 [DOI] [PMC free article] [PubMed] [Google Scholar]
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Aliya Rehmani , Palak Ghanshyam Rahangdale , Payal Dilip Meshram
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.